Catalyst Pharmaceuticals Inc [CPRX] stock is trading at $15.79, up 1.81%. An important factor to consider is whether the stock is rising or falling in short-term value. The CPRX shares have gain 3.47% over the last week, with a monthly amount drifted -2.83%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, March 2024, Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day. In a post published today on Yahoo Finance, Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult-to-treat diseases, today announced its endorsement of the inaugural Lambert-Eaton myasthenic syndrome (“LEMS”) Awareness Day. This landmark event, now officially observed annually on March 30th, signifies a meaningful milestone for the LEMS community. The chosen date holds profound historical significance, coinciding with the publication of Dr. Edward Lambert and Dr. Lee Eaton’s pioneering research on LEMS, which has greatly advanced the understanding and treatment of this rare neuromuscular disorder.
From an analyst’s perspective:
Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] stock has seen the most recent analyst activity on March 14, 2024, when Citigroup initiated its Buy rating and assigned the stock a price target of $27. Previously, BofA Securities started tracking the stock with Buy rating on March 07, 2024, and set its price target to $23. On December 21, 2023, Oppenheimer initiated with a Outperform rating and assigned a price target of $30 on the stock. ROTH Capital downgraded its rating to a Neutral and increased its price target to $15.50 on August 24, 2022. Cantor Fitzgerald initiated its recommendation with a Overweight. In a note dated October 05, 2016, Piper Jaffray upgraded an Overweight rating on this stock.
Catalyst Pharmaceuticals Inc [CPRX] stock has fluctuated between $11.09 and $18.22 over the past year. Currently, Wall Street analysts expect the stock to reach $19.38 within the next 12 months. Catalyst Pharmaceuticals Inc [NASDAQ: CPRX] shares were valued at $15.79 at the most recent close of the market. An investor can expect a potential return of 22.74% based on the average CPRX price forecast.
Analyzing the CPRX fundamentals
Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] reported sales of 398.20M for the trailing twelve months, which represents a growth of 81.98%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.22%, Pretax Profit Margin comes in at 0.24%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.2 and Total Capital is 0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.54 points at the first support level, and at 15.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.93, and for the 2nd resistance point, it is at 16.07.
Catalyst Pharmaceuticals Inc [CPRX] reported earnings per share of $0.31 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.26/share, meaning a difference of $0.05 and a surprise factor of 19.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.29 per share as compared to estimates of -$0.28 per share, a difference of -$0.01 representing a surprise of -3.60%.
Ratios To Look Out For
For context, Catalyst Pharmaceuticals Inc’s Current Ratio is 2.88. On the other hand, the Quick Ratio is 2.68, and the Cash Ratio is 1.81. Considering the valuation of this stock, the price to sales ratio is 4.67, the price to book ratio is 4.36 and price to earnings (TTM) ratio is 25.92.
Transactions by insiders
Recent insider trading involved Elsbernd Brian, Chief Compliance/Legal Officer, that happened on Mar 27 ’24 when 25000.0 shares were sold. Director, Harper Molly completed a deal on Dec 15 ’23 to sell 14000.0 shares. Meanwhile, Director Tierney David S sold 50000.0 shares on Dec 12 ’23.
